EIB finances with €15 million Amadix to develop innovative diagnostic tests for early cancer detection

• Amadix is a Spanish biotech company developing non-invasive blood tests for early detection of several types of cancer before the symptoms appear.
• The financing is part of the support the EIB is providing to European medtech startups developing cutting-edge medical solutions and contributes to the EIB Group strategic priority of accelerating digitalisation and technological innovation.
• The operation is supported by InvestEU, an EU programme that aims to unlock over €372 billion in investment by 2027.

https://www.eib.org/en/press/all/2025-058-eib-finances-with-eur15-million-amadix-to-develop-innovative-diagnostic-tests-for-early-cancer-detection